The Juvenile Diabetes Research Foundation (JDRF) and medical firm KalVista Pharmaceuticals have launched a research partnership to explore a new approach to preserving vision and slowing down the progression of diabetic eye disease, a common complaint for patients with type 1 diabetes.
JDRF will offer up to USD2.2 million in overall support and research expertise to KalVista to help advance its plasma kallikrein inhibitor for clinical trials, as well as to achieve data on its potential for treating diabetic macular edema (DME). DME involves swelling in the retina that impairs vision, and can happen at any time during diabetic retinopathy.
Plasma kallikrein is a potential therapeutic target for patients with DME, as its activation raises the inflammation and permeability of blood vessels by producing bradykini, a hormone that causes blood vessels to dilate or enlarge. Plasma kallikrein inhibitors are therefore thought to lower retinal vessel leakage as they are able to suppress excessive production of bradykinin.
Aaron Kowalskin, assistant vice president of treatment therapies for JDRF, commented “What makes our collaboration with KalVista so exciting is that we are gradually seeing this novel therapy, which could represent a whole new approach to treating DME, move from basic research discovery into a potential commercially viable drug with the help of JDRF funding.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…